Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies

Pathology

Volumn 43, Issue 6, 2011, Pages 525-535

  Khaw, Seong Lin ^a,b,c,d,e   Huang, David C S ^a,c,d   Roberts, Andrew W ^a,b,c,d  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ACRF Centre for Therapeutic Target Discovery   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH MEDICAL CENTRE   (Australia)

Author keywords

Apoptosis; Bcl 2; BH3 mimetic; Leukaemia; Lymphoma; Navitoclax

Indexed keywords

EID: 83055173306     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834b1b34     Document Type: Article

References (123)

1. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenom-enon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
2. Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-306. (Pubitemid 11219226)
3. Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase- independent effector of cell death. Cell Death Differ 1999; 6: 516-24. (Pubitemid 29292107)
4. Vince JE, Wong WW, Khan N, et al. IAP antagonists target c IAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-93. (Pubitemid 350103599)
5. Zong W. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481-6. (Pubitemid 32552527)
6. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30. (Pubitemid 32385543)
7. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-9.
8. Fletcher JI, Meusburger S, Hawkins CJ, et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci USA 2008; 105: 18081-7.
9. Willis SN, Chen L, Dewson G, et al. Pro-apoptotic Bak is sequestered by Mc1-1 and Bcl-x L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-305. (Pubitemid 41003019)
10. Chen L, Willis SN, Wei A, et al. Differential targeting ofpro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005; 17: 393-403. (Pubitemid 40193310)
11. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005; 12: 1008-14. (Pubitemid 41065418)
12. Ekoff M, Kaufmann T, Engstrom M, et al. The BH3-only protein Puma plays an essential role in cytokine deprivation-induced apoptosis of mast cells. Blood 2007; 110: 3209-17. (Pubitemid 350106313)
13. Coultas L, Terzano S, Thomas T, et al. Hrk/DP5 contributes to the apoptosis of select neuronal populations but is dispensable for haemato-poietic cell apoptosis. J Cell Sci 2007; 120: 2044-52. (Pubitemid 47010000)
14. You H, Pellegrini M, Tsuchihara K, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006; 203: 1657-63. (Pubitemid 44036270)
15. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005; 202: 1363-74. (Pubitemid 41668739)
16. Opferman JT. Apoptosis in the development of the immune system. Cell Death Differ 2008; 15: 234-42.
17. Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S. The anti-apoptotic activities of rel and Rel A required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J 2000; 19: 6351-60.
18. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91. (Pubitemid 26008141)
19. Puthalakath H, Villunger A, O'Reilly LA, et al. Bmf: a pro-apoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001; 293: 1829-32. (Pubitemid 32845780)
20. Evan GI,Wyllie AH, Gilbert CS, etal.Induction of apoptos is infibroblasts by c-myc protein. Cell 1992; 69: 119-28.
21. Evan G, Littlewood T. Amatter of life and cell death. Science 1998; 281: 1317-21.
22. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003; 302: 1036-8. (Pubitemid 37386194)
23. Hanahan D, Weinberg RA. Hallmarks ofcancer: the next generation. Cell 2011; 144: 646-74.
24. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-3. (Pubitemid 15041322)
25. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
26. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-3. (Pubitemid 120029100)
27. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 2007; 26: 1306-16. (Pubitemid 46328472)
28. Wilda M, Bruch J, Harder L, et al. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia 2004; 18: 584-8. (Pubitemid 38425874)
29. Carter TL, Watt PM, Kumar R, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood 2001; 97: 572-4. (Pubitemid 32060347)
30. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-84. (Pubitemid 34864269)
31. Iglesias-Serret D, De Frias M, Santidrián AF, et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007; 21: 281-7. (Pubitemid 46158121)
32. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-8. (Pubitemid 129515880)
33. Bachmann PS, Gorman R, Mackenzie KL, Lutze-Mann L, Lock RB. Dexamethasone resistance in B-cell precursor childhood acute lympho-blastic leukemia occurs downstream of ligand-induced nuclear transloca-tion of the glucocorticoid receptor. Blood 2005; 105: 2519-26. (Pubitemid 40387054)
34. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3-mimetic. Proc Natl Acad Sci USA 2006; 103: 14907-12. (Pubitemid 44527827)
35. Lindemann RK, Newbold A, Whitecross KF, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071-6. (Pubitemid 47185877)
36. Xargay-Torrent S, Lopez-Guerra M, Saborit-Villarroya I, et al. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-onlygenepromoters. Clin Cancer Res2011;17:3956-68.
37. Schmitt CA, Rosenthal CT, Lowe SW. Genetic analysis of chemoresis-tance in primary murine lymphomas. Nat Med 2000; 6: 1029-35.
38. Huang DCS, O'Reilly LA, Strasser A, Cory S.Theanti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16: 4628-38. (Pubitemid 27326600)
39. Miyashita TRJ. Bcl-2 oncoprotein blocks chemotherapy induced apop-tosis in a human leukemia cell line. Blood 1993; 81: 151.
40. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407-11.
41. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y. Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-6. (Pubitemid 24146774)
42. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechan-isms inhibitable by Bcl-2. Cell 1994; 79: 329-39.
43. Huang DCS, Cory S, Strasser A. Bcl-2, Bcl-XL and adenovirus protein E1B19 k D are functionally equivalent in their ability to inhibit cell death. Oncogene 1997; 14: 405-14. (Pubitemid 27087103)
44. Gibson L, Holmgreen S, Huang DCS, et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 1996; 13: 665-75. (Pubitemid 26312893)
45. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89: 630-43. (Pubitemid 27051700)
46. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-8.
47. van Delft MF, Wei AH, Mason KD, et al. The BH3-mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-99. (Pubitemid 44711953)
48. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-81. (Pubitemid 40825512)
49. Mason KD, Vandenberg CJ, Scott C, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008; 105: 17961-6.
50. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176-83.
51. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that upregulate of MCL-1 and BFL-1. Blood 2010.
52. Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1)of the BH3-mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer2008; 50: 1181-9. (Pubitemid 351555542)
53. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3-mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-88. (Pubitemid 44693472)
54. Mason KD, Khaw SL, Rayeroux KC, et al. The BH3-mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009; 23: 2034-41.
55. Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-13.
56. Whitecross KF, Alsop AE, Cluse LA, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009; 113: 1982-91.
57. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171-85. (Pubitemid 47199122)
58. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117:112-21. (Pubitemid 46048458)
59. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
60. Trudel S, Li Z, Rauw J, Tiedemann R, Wen X, Stewart A. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007; 109: 5430-8. (Pubitemid 46890566)
61. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resis-tance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512-7.
62. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010; 120: 1310-23.
63. Meng Y, Tang W, Dai Y, et al. Natural BH3-mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-x L inhibition accompa-nied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7: 2192-202.
64. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3-mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004; 10: 7757-63. (Pubitemid 39557541)
65. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossy-pol] against diffuse large cell lymphoma. Mol Cancer Ther 2005; 4: 13-21. (Pubitemid 40268062)
66. Balakrishnan K, Wierda W, Keating M, Gandhi V. Gossypol, a BH3-mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008; 112: 1971-80.
67. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008; 14: 3268-77.
68. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-86. (Pubitemid 46427871)
69. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of Phase 1 study of navitoclax (ABT-263) in patients with relapsed or refractory disease. J Clin Oncol 2011; 29: (in press).
70. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-59.
71. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-16.
72. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009; 114: 663-6.
73. Schoenwaelder SM, Jarman KE, Gardiner E, et al. Bcl-x L inhibitory BH3-mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;Jun 14: (Epubaheadofprint).
74. Mason KD, Vandenberg CJ, Scott CL, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008; 105: 17961-6.
75. Clinical Trials.gov Search of: ABT-263. 2011 (cited 12 July 2011). http://clinicaltrials.gov/ct2/results?term=ABT-263
76. Clinical Trials.gov Search of: Obatoclax. 2011 (cited 12 July 2011). http://clinicaltrials.gov/ct2/results?term=obatoclax
77. Hwang JJ, Kuruvilla J, Mendelson D, et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010; 16: 4038-45.
78. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113: 299-305.
79. Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clinical Cancer Res 2008; 14: 8295-301.
80. Raza A, Galili N, Borthakur G, et al. A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol 2009; 27: 3579.
81. Clinical Trials.gov Search of: AT-101. 2011 (cited 12 July 2011). http://clinicaltrials.gov/ct2/results?term=AT-101
82. James DF, Castro JE, Loria O, Prada CE, Aguillon RA, Kipps JK. AT-101, a small molecule Bcl-2 antagonist, in treatment na?̈ve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial. J Clin Oncol 2006; 24: 6605.
83. Liu G, Kelly WK,Wilding G,Leopold L, Brill K, Somer B. Anopen-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistantprostate cancer. Clin Cancer Res 2009; 15: 3172-6.
84. Kingsley E, Richards D, Garbo L, et al. An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). J Clin Oncol 2009; 27: 8582.
85. Hartung L, Bahler DW. Flow cytometric analysis of BCL-2 can distin-guish small numbers of acute lymphoblastic leukaemia cells from B-cell precursors. Br J Haematol 2004; 127: 50-8. (Pubitemid 39331106)
86. Menendez P, Vargas A, Bueno C, et al. Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leuke-mia 2004; 18: 491-8. (Pubitemid 38425863)
87. Bhojwani D, Kang H, Menezes RX, et al. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 2008; 26: 4376-84.
88. Salomons GS, Smets LA, Verwijs-Janssen M, et al. Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia 1999; 13: 1574-80. (Pubitemid 29465620)
89. Coustan-Smith E, Kitanaka A, Pui CH, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87: 1140-6. (Pubitemid 26043542)
90. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008; 111: 2300-9. (Pubitemid 351451437)
91. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-40. (Pubitemid 350022448)
92. Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007; 110: 2057-66. (Pubitemid 47443923)
93. High LM, Szymanska B, Wilczynska-Kalak U, et al. The Bcl-2 homology domain 3mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010; 77: 483-94.
94. Stam RW, Den Boer ML, Schneider P, et al. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearrangedinfantacutelymphoblastic leukemia. Blood 2010; 115: 1018-25.
95. Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116: 3013-22.
96. Campos L, Rouault JP, Sabido O, et al. Highexpression of bcl-2proteinin acute myeloid leukemia cells is associated with poor response to che-motherapy. Blood 1993; 81: 3091-6. (Pubitemid 23162130)
97. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptoticregulator Mcl-1 atthetime of leukemicrelapse. Blood 1998; 91: 991-1000. (Pubitemid 28078303)
98. Fennell DA, Corbo MV, Dean NM, Monia BP, Cotter FE. In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leu-kaemia cell death in a SCID/NOD-Hu model. Br J Haematol 2001; 112: 706-13. (Pubitemid 32222845)
99. Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood 2011; 117: 2237-40.
100. Ricciardi MR, Mc Queen T, Chism D, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005; 19: 1543-9. (Pubitemid 43090397)
101. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358-65. (Pubitemid 44497520)
102. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22: 808-18. (Pubitemid 351552630)
103. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-9.
104. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemother-apy. Blood 2006; 108: 3262-70.
105. Knapper S, Mills KI, Gilkes AF, Austin SJ, Walsh V, Burnett AK. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 2006; 108: 3494-503.
106. Kohl TM, Hellinger C, Ahmed F, et al. BH3-mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007; 21: 1763-72. (Pubitemid 47086765)
107. Nordigarden A, Kraft M, Eliasson P, et al. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying onco-genic FLT3. Blood 2009; 113: 2302-11.
108. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010; 10: 23-36.
109. Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-x L, and Mcl-1. Mol Cell Biol 2009; 29: 6149-69.
110. Kuroda J, Kimura S, Andreeff M, et al. ABT-737is auseful componentof combinatory chemotherapies for chronic myelogenous leukaemias with diverse drug resistance mechanisms. Br J Haematol 2008; 140: 181-90. (Pubitemid 350265045)
111. Li G, Miskimen KL, Wang Z, et al. Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia 2010; 24: 1397-405.
112. Evangelisti C, Ricci F, Tazzari P, et al. Targeted inhibition of m TORC1 and m TORC2 by active-site m TOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781-91.
113. Shah OJ, Lin X, Li L, et al. Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proc Natl Acad Sci USA 2010; 107: 12634-9.
114. Li M, Chen F, Clifton N, et al. Combinedinhibition of Notch signalingand Bcl-2/Bcl-x L results in synergistic antimyeloma effect. Mol Cancer Ther 2010; 9: 3200-9.
115. Khaw SL, Huang DC, He S, et al. Biomarkers andinvivoresponsestothe BH3-mimetic, ABT-263, in patients (pts) with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2009; 114: 2374.
116. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008; 112: 5141-9.
117. Herold M. The stability and anti-apoptotic function of A1 are controlled by its C terminus. J Biol Chem 2006; 281: 13663-71. (Pubitemid 43855282)
118. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol 1995; 128: 1173-84.
119. Yang T, Buchan HL, Townsend KJ, Craig RW. MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differ-entiation or death, but not to signals for cell proliferation. J Cell Physiol 1996; 166: 523-36.
120. Calin GA, Ferracin M, Cimmino A, et al. A Micro RNA signature associated with prognosis and progression in chronic lymphocytic leu-kemia. N Engl J Med 2005; 353: 1793-801. (Pubitemid 41549891)
121. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-9. (Pubitemid 41377683)
122. Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemother-apeutics is regulated by MCL1 and FBW7. (Erratum in: Nature. 2011; 475: 122.). Nature 2011; 471: 110-4.
123. Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-7.